Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

St. Jude Medical Announces CE Mark Approval Of Ellipse ICD - Quick Facts

St. Jude Medical, Inc. (STJ: Quote) announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator, or ICD. ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms that often lead to sudden cardiac death.

According to the company, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.

Dr. L.R.C. Dekker, cardiologist from the Cardiac Center of the Catharina Hospital in Eindhoven, The Netherlands, who implanted the first Ellipse ICD in Europe, said, "Its thinness, longevity and new discrimination algorithms constitute the answers to the three main concerns of patients and their doctors: decreasing the volume of the can, reducing the risk for infection during ICD replacement and minimizing inappropriate shock."

Click here to receive FREE breaking news email alerts for St. Jude Medical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps will retain his vice president of product title and work on Twitter's geolocation features, the Wall Street... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Visa Inc., the world's largest payment card processor, said Wednesday that its fourth quarter profit fell 10% from last year, hurt mainly by a hefty litigation provision even as revenue increased 9%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.